

# Laura K Ferris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8617365/publications.pdf>

Version: 2024-02-01

75  
papers

2,427  
citations

186265

28  
h-index

214800

47  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3371  
citing authors

#	ARTICLE	IF	CITATIONS
1	BAP1 regulates IP3R3-mediated Ca <sup>2+</sup> flux to mitochondria suppressing cell transformation. <i>Nature</i> , 2017, 546, 549-553.	27.8	308
2	Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 780-785.e3.	1.2	148
3	Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. <i>BMC Cancer</i> , 2018, 18, 130.	2.6	117
4	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blind trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.5	117
5	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 432-440.e17.	1.2	111
6	Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 114-120.e2.	1.2	107
7	The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 667-674.	1.2	89
8	COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1274-1284.	1.2	82
9	Computer-aided classification of melanocytic lesions using dermoscopic images. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 769-776.	1.2	79
10	Accuracy of Skin Cancer Diagnosis by Physician Assistants Compared With Dermatologists in a Large Health Care System. <i>JAMA Dermatology</i> , 2018, 154, 569.	4.1	67
11	Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy. <i>JAMA Dermatology</i> , 2017, 153, 675.	4.1	64
12	Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. <i>Archives of Dermatological Research</i> , 2017, 309, 243-251.	1.9	62
13	Smartphone-Based Applications for Skin Monitoring and Melanoma Detection. <i>Dermatologic Clinics</i> , 2017, 35, 551-557.	1.7	62
14	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. <i>Cancer Prevention Research</i> , 2018, 11, 429-438.	1.5	59
15	Human Beta-Defensin 3 Induces Maturation of Human Langerhans Cell-Like Dendritic Cells: An Antimicrobial Peptide that Functions as an Endogenous Adjuvant. <i>Journal of Investigative Dermatology</i> , 2013, 133, 460-468.	0.7	53
16	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
17	A Large Skin Cancer Screening Quality Initiative. <i>JAMA Oncology</i> , 2017, 3, 1112.	7.1	50
18	Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions. <i>Melanoma Research</i> , 2018, 28, 478-482.	1.2	47

#	ARTICLE	IF	CITATIONS
19	Efficacy, Safety, and Out-of-pocket Costs are the Most Important Factors to Patients in Choosing a Psoriasis Therapy. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 30-3.	0.1	47
20	Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 818-825.e3.	1.2	44
21	Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR). <i>British Journal of Dermatology</i> , 2017, 177, 1552-1561.	1.5	44
22	Utilization of Asynchronous and Synchronous Teledermatology in a Large Health Care System During the COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2021, 27, 771-777.	2.8	44
23	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	3.0	40
24	Estimating the cost of skin cancer detection by dermatology providers in a large health care system. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 701-709.e1.	1.2	38
25	Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 152-159.	2.2	38
26	Downstream consequences of melanoma screening in a community practice setting: First results. <i>Cancer</i> , 2016, 122, 3152-3156.	4.1	35
27	Risk of Subsequent Cutaneous Melanoma in Moderately Dysplastic Nevi Excisionally Biopsied but With Positive Histologic Margins. <i>JAMA Dermatology</i> , 2018, 154, 1401.	4.1	30
28	Surveillance of Patients for Early Detection of Melanoma. <i>Archives of Dermatology</i> , 2011, 147, 673.	1.4	29
29	Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. <i>JAMA Dermatology</i> , 2022, 158, 504.	4.1	26
30	Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules. <i>Molecular Medicine Reports</i> , 2016, 14, 3935-3940.	2.4	20
31	Psychosocial consequences of skin cancer screening. <i>Preventive Medicine Reports</i> , 2018, 10, 310-316.	1.8	20
32	Noninvasive Analysis of High-Risk Driver Mutations and Gene Expression Profiles in Primary Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1127-1134.	0.7	19
33	Women's Experiences With Isotretinoin Risk Reduction Counseling. <i>JAMA Dermatology</i> , 2014, 150, 366.	4.1	18
34	Epidemiology of Ophthalmologic Disease Associated with Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis in Hospitalized Children in the United States. <i>Pediatric Dermatology</i> , 2014, 31, 163-168.	0.9	18
35	Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 755-760.	2.3	18
36	Indoor Tanning, Skin Cancer and the Young Female Patient: A Review of the Literature. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2015, 28, 275-283.	0.7	17

#	ARTICLE	IF	CITATIONS
37	Patient Preferences During Skin Cancer Screening Examination. <i>JAMA Dermatology</i> , 2016, 152, 1052.	4.1	14
38	Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1023-1024.	1.2	14
39	Quality of Life Assessed Using Skindex-16 Scores Among Patients With Acne Receiving Isotretinoin Treatment. <i>JAMA Dermatology</i> , 2020, 156, 1098.	4.1	14
40	Melanoma depth in patients with an established dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 841-846.	1.2	13
41	Promoting Safe Use of Isotretinoin by Increasing Contraceptive Knowledge. <i>JAMA Dermatology</i> , 2015, 151, 389.	4.1	12
42	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2729-2739.	2.3	11
43	Topical electrophilic nitro-fatty acids potentiate cutaneous inflammation. <i>Free Radical Biology and Medicine</i> , 2018, 115, 31-42.	2.9	11
44	Electrophilic nitro-fatty acids suppress psoriasisform dermatitis: STAT3 inhibition as a contributory mechanism. <i>Redox Biology</i> , 2021, 43, 101987.	9.0	11
45	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	2.4	11
46	Benefits to patient care of electronically capturing patient-reported outcomes in dermatology. <i>British Journal of Dermatology</i> , 2019, 181, 826-827.	1.5	9
47	Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. <i>Journal of Clinical Oncology</i> , 2016, 34, 9581-9581.	1.6	9
48	We Pledge to Change iPLEDGE. <i>JAMA Dermatology</i> , 2015, 151, 701.	4.1	8
49	Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 461-466.	1.2	7
50	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	3.0	7
51	Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2564-2572.	2.3	6
52	Re-evaluating the ABCD criteria using a consecutive series of melanomas. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1161-1163.	1.2	6
53	Early Detection of Melanoma. <i>JAMA Dermatology</i> , 2021, 157, 511.	4.1	6
54	Dose-response evaluation of broccoli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN). <i>Journal of Clinical Oncology</i> , 2016, 34, e21022-e21022.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Trends in List and Net Prices of Self-administered Systemic Psoriasis Therapies Manufactured by US-Based Pharmaceutical Companies. <i>JAMA Dermatology</i> , 2020, 156, 1136.	4.1	4
56	Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians. <i>JAMA Dermatology</i> , 2021, 157, 189.	4.1	4
57	Impact on clinical practice of a non-invasive gene expression melanoma rule-out test: 12-month follow-up of negative test results and utility data from a large US registry study. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	4
58	A cross-sectional study of indoor tanning use among patients seeking skin cancer screening. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 164-165.	1.2	3
59	Melanoma toolkit for early detection for primary care providers: A pilot study. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 984-986.	3.3	3
60	A Systematic Review of Concomitant Bullous Pemphigoid and Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 1, 150-158.	0.7	2
61	The Value of Behavioral Counseling for Skin Cancer Prevention. <i>JAMA Oncology</i> , 2018, 4, 630.	7.1	2
62	Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey. <i>British Journal of Dermatology</i> , 2019, 180, 664-665.	1.5	2
63	Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. <i>JAMA Dermatology</i> , 2021, 157, 876-879.	4.1	2
64	Mutations in the SC4MOL gene encoding a novel methyl sterol oxidase cause autosomal recessive psoriasisiform dermatitis, microcephaly and developmental delay. <i>Nature Precedings</i> , 2008, , .	0.1	1
65	Could testing for BAP1 germline mutations be a useful tool for early melanoma diagnosis?. <i>Expert Review of Dermatology</i> , 2013, 8, 107-109.	0.3	1
66	Reply to: "Computer-aided classification of melanocytic lesions using dermoscopic images: Low reported accuracy for reader study on melanomas with low melanoma in situ to invasive melanoma ratio". <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e121.	1.2	1
67	Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 587-590.	1.2	1
68	Reply to: "Comment on "Re-evaluating the ABCD criteria using a consecutive series of melanomas". <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e299.	1.2	1
69	Preliminary outcomes of a primary care-based skin cancer screening program.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1508-1508.	1.6	1
70	Correlation Between the Evaluation of Pigmented Lesions by a Multi-spectral Digital Skin Lesion Analysis Device and the Clinical and Histological Features of Melanoma. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 36-8.	0.1	1
71	Should there be an app for that? Controversies of diagnosing melanoma with your smartphone. <i>Expert Review of Dermatology</i> , 2013, 8, 221-223.	0.3	0
72	Predictors of thick and lethal melanoma in white young adults in the United States. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 198-200.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Performance of Dermatology Physician Assistantsâ€™ Reply. JAMA Dermatology, 2018, 154, 1229.	4.1	0
74	Screening and Managing Melanoma: Who Is (Should Be) Doing It?. Current Dermatology Reports, 2019, 8, 164-171.	2.1	0
75	A pragmatic approach to melanoma screening in collaboration with primary care providers. Cutis, 2016, 97, 382-3.	0.3	0